Table 1 Baseline characteristics of the study population (N = 16).
Variable description | N = 16 | Reference values |
|---|---|---|
Age (years) Mean (SD) | 41.5 (13.3) | – |
Gender (male) N (%) | 12 (75) | – |
AST median (IQR) U/L | 50 (27, 124) | 5–40 |
ALT (U/L) Median (IQR) | 56 (22, 160) | 7–56 |
ALP (U/L) Median (IQR) | 115 (97, 145) | 44–147 |
Albumin (g/L) Median (IQR) | 34 (25, 38) | 35–50 |
Neutrophils (× 103 cells/µL) Median (IQR) | 2.5 (23.5, 67) | 2–7 |
Eosinophils (× 103 cells/μL) Median (IQR) | 4.5 (2.4, 7.5) | 0.0–0.5 |
EGFR*7 (mL/min/1.73 m2 Median (IQR) | 60 (60, 107) | > 60 |
Drug latent period (days) Median (IQR) | 14 (6.4, 29.2) | – |
Extent of skin rash (> 50%) | 9/16 | |
Internal organ involvement | ||
Liver (%) | 25 | |
Kidneys (%) | 37.5 | |
RegiSCAR Median (IQR) | 6 (5, 6.8) | |
J-SCAR Median (IQR) | 5 (4, 5.8) | |
Proportion of EBV positivity (%) | 31.2 | |